Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 19

BillFederalHouseIn Committee
Lower Costs, More Cures Act of 2019
About This Bill
Committee
Latest Action · December 19, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Congress
116th (2019–2021)
Introduced
December 9, 2019
Cosponsors (147)
0D 147R
View PDF ↗

Summary

Highlight any text to annotate
Lower Costs, More Cures Act of 2019 This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs. The bill generally limits payment amounts for drugs and biologics under Medicare medical services, reduces cost-sharing under the Medicare prescription drug benefit, modifies certain authorities and requirements under the Medicaid Drug Rebate Program, revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and establishes several reporting requirements for drug manufacturers with respect to drug prices.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.